Cargando…
Dynamic (18)F‐FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non‐small cell lung cancer
Major pathological response (MPR) is a potential surrogate for overall survival. We determined whether the dynamic changes in (18)F‐labeled fluoro‐2‐deoxyglucose positron emission tomography/computed tomography ((18)F‐FDG PET/CT) were associated with MPR in patients receiving neoadjuvant immunothera...
Autores principales: | Chen, Zhi‐Yong, Fu, Rui, Tan, Xiao‐Yue, Yan, Li‐Xu, Tang, Wen‐Fang, Qiu, Zhen‐Bin, Qi, Yi‐Fan, Li, Yu‐Fa, Hou, Qing‐Yi, Wu, Yi‐Long, Zhong, Wen‐Zhao, Jiang, Ben‐Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436661/ https://www.ncbi.nlm.nih.gov/pubmed/35822254 http://dx.doi.org/10.1111/1759-7714.14562 |
Ejemplares similares
-
Comments on “dynamic
(18)F‐FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non‐small cell lung cancer”
por: Wang, Shan‐Ying, et al.
Publicado: (2022) -
Pulmonary Findings of [(18)F]FDG PET/CT Images on Asymptomatic COVID-19 Patients
por: Ho, Tzu-Chuan, et al.
Publicado: (2021) -
[(18)F]FDG PET/CT in the Evaluation of Melanoma Patients Treated with Immunotherapy
por: Mangas Losada, María, et al.
Publicado: (2023) -
(18)F‐FDG PET/CT predicts the role of neoadjuvant immunochemotherapy in the pathological response of esophageal squamous cell carcinoma
por: Wang, Shuohua, et al.
Publicado: (2023) -
The efficiency of (18)F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer
por: Tao, Xiuli, et al.
Publicado: (2020)